Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis

Journal of Investigational Allergology and Clinical Immunology

Volumn 19, Issue 6, 2009, Pages 459-464

  Schaper C ^a   Gustavus, B ^b   Koch, B ^a   Ewert, R ^a   Hanf, G ^b   Kunkel, G ^b   Noga, O ^b   Glaser S ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Fexofenadine; Inflammation; Intermittent allergic rhinitis

Indexed keywords

ALBUMIN; EOSINOPHIL CATIONIC PROTEIN; FEXOFENADINE; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; PEPTIDOLEUKOTRIENE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIRCH; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; HAY FEVER; HUMAN; MALE; NOSE AIRFLOW; NOSE EDEMA; NOSE MUCUS; NOSE SECRETION; NOSE SMEAR; POLLEN; RHINOMANOMETRY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIGENS, PLANT; ARTEMISIA; BETULA; DISEASE PROGRESSION; EOSINOPHIL CATIONIC PROTEIN; FEMALE; HISTAMINE; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; LEUKOTRIENE D4; MALE; MIDDLE AGED; NASAL LAVAGE FLUID; POLLEN; RHINITIS, ALLERGIC, SEASONAL; TERFENADINE; TREATMENT OUTCOME;

EID: 74849096173     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Ait-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 Suppl 86:8-160.
2. Ciprandi G, Marseglia GL, Klersy C, Tosca MA. Relationships between allergic inflammation and nasal airflow in children with persistent allergic rhinitis due to mite sensitization. Allergy. 2005 Jul;60(7):957-60.
3. Ciprandi G, Passalacqua G. Allergy and the nose. Clin Exp Immunol. 2008 Sep;153 Suppl 1:22-6.
4. Naclerio RM. Pathophysiology of perennial allergic rhinitis. Allergy. 1997;52(36 Suppl):7-13.
5. Naclerio RM, Proud D, Togias AG, Adkinson NF, Jr., Meyers DA, Kagey-Sobotka A, Plaut M, Norman PS, Lichtenstein LM. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med. 1985 Jul 11;313(2):65-70.
6. Trigg CJ, Davies RJ. Local antihistamines. Clin Exp Allergy. 1996 Oct;26(10):1108-11.
7. Vignola AM, Campbell AM, Chanez P, Lacoste P, Michel FB, Godard P, Bousquet J. Activation by histamine of bronchial epithelial cells from nonasthmatic subjects. Am J Respir Cell Mol Biol. 1993 Oct;9(4):411-7.
8. Naclerio RM. Inhibition of mediator release during the early reaction to antigen. J Allergy Clin Immunol. 1992 Oct;90(4 Pt 2):715-9.
9. Carr WW, Nelson MR, Hadley JA. Managing rhinitis: Strategies for improved patient outcomes. Allergy Asthma Proc. 2008 Jul-Aug;29(4):349-57.
10. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999 Nov;104(5):927-33.
11. Philpot EE. Safety of second generation antihistamines. Allergy Asthma Proc. 2000 Jan-Feb;21(1):15-20.
12. Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000 Jun;30(6):891-9.
13. Church MK. Non-H1-receptor effects of antihistamines. Clin Exp Allergy. 1999 Jul;29 Suppl 3:39-48.
14. Lippert U, Kruger-Krasagakes S, Moller A, Kiessling U, Czarnetzki BM. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol. 1995 Aug;4(4 Pt 2):272-6.
15. Eda R, Townley RG, Hopp RJ. Effect of terfenadine on human eosinophil and neutrophil chemotactic response and generation of superoxide. Ann Allergy. 1994 Aug;73(2):154-60.
16. Devalia JL, Davies RJ. Effect of antihistamines on epithelial cells. Clin Exp Allergy. 1999 Jul;29 Suppl 3:64-8; discussion 9-71.
17. Howarth PH. The cellular basis for allergic rhinitis. Allergy. 1995;50(23 Suppl):6-10.
18. Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy. 1999 Jul;29 Suppl 3:163-70; discussion 71-3.
19. Siraganian RP. An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal Biochem. 1974 Feb;57(2):383-94.
20. Kim D, Baraniuk JN. Neural aspects of allergic rhinitis. Curr Opin Otolaryngol Head Neck Surg. 2007 Aug;15(4):268-73.
21. Wilson SJ, Lau L, Howarth PH. Inflammatory mediators in naturally occurring rhinitis. Clin Exp Allergy. 1998 Feb;28(2):220-7.
22. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs. 2000 Feb;59(2):301-21.
23. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1998 Mar;101(3):410-20.
24. Terrien MH, Rahm F, Fellrath JM, Spertini F. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. J Allergy Clin Immunol. 1999 Jun;103(6):1025-30.
25. Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, Allen M, Marseglia GL. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005 Dec;5(13-14):1800-8.
26. Marone G, Gentile M, Petraroli A, De Rosa N, Triggiani M. Histamine-induced activation of human lung macrophages. Int Arch Allergy Immunol. 2001 Jan-Mar;124(1-3):249-52.
27. Abdelaziz MM, Khair OA, Devalia JL. The potential of active metabolites of antihistamines in the management of allergic disease. Allergy. 2000 May;55(5):425-34.
28. Vignola AM, Crampette L, Mondain M, Sauvere G, Czarlewski W, Bousquet J, Campbell AM. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy. 1995 Mar;50(3):200-3.
29. Ciprandi G, Cirillo IG, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study. Eur Ann Allergy Clin Immunol. 2005 Jan;37(1):25-9.